Atorvastatin

Limits on what this shows

• Key negative / null findings: Mitochondrial content was unchanged throughout the human trial: citrate synthase activity and mitochondrial protein complex expression did not differ from baseline. Complex I and II activities were unaffected. Creatine kinase, the standard clinical marker of muscle injury, stayed within normal limits throughout. Group-mean VO2 max did not change significantly, though 5 of 8 individuals showed declines of 4.3 to 16.5 percent, an inconsistent individual-level signal sitting inside a null group-level average.
• At-risk subgroups: Defined only by dose in the available data: all 8 subjects received the maximum labeled 80 mg/day. Whether standard doses (10 to 40 mg) produce a smaller or absent effect has not been tested directly in humans.
• Dose and duration: 80 mg/day for up to 56 days is the only human exposure tested. The in vitro complex IV inhibition, however, occurred at 10 nM, a concentration at or below typical peak plasma levels even at standard doses, which argues against a clean high-dose-only threshold and is the main reason this entry is not graded lower than orange despite the in vivo data covering only the top of the dose range.

Regulatory status

Mitochondria and mitochondrial function are not named anywhere in the atorvastatin prescribing information.

Population evidence

Ryan TE, Torres MJ, Lin CT, et al. High-dose atorvastatin therapy progressively decreases skeletal muscle mitochondrial respiratory capacity in humans. JCI Insight. 2024. PMID 38385748. Repeated-measures trial, 8 overweight but otherwise healthy sedentary adults, atorvastatin 80 mg/day for 56 days with measurements at baseline, day 14, day 28, and day 56. Maximal ADP-stimulated respiration in permeabilized skeletal muscle fiber bundles declined progressively, reaching a greater than 30 percent loss of oxidative phosphorylation capacity by day 56 (repeated-measures ANOVA with Dunnett's test, p<0.05 at days 28 and 56, not at day 14). The same paper's in vitro work found atorvastatin inhibited complex IV activity by roughly 50 percent at 10 nM and complex III by roughly 70 percent at 1.5 mM, direct evidence the drug itself, not only reduced CoQ10 supply, can inhibit the electron transport chain.

Mechanism

Named, and distinct from the CoQ10 finding graded red above. CoQ10 depletion reduces the supply of a mobile electron carrier feeding complexes I and III; the complex IV inhibition demonstrated here is direct enzyme inhibition of cytochrome c oxidase, a different protein target downstream of where CoQ10 acts, and was potent at nanomolar concentrations in vitro.

Tier history

At the September 5, 2026 review this tier was printed as empty. That entry is retired here and its reasoning is preserved verbatim, because it remains accurate as written and documents what changed. It read: "Orange requires at least one Tier A source with atorvastatin in the cohort showing a real but bounded deficit for a different nutrient. Nothing besides CoQ10 (graded red) reached that bar." Why it was empty: "Vitamin K2 and selenium mechanisms located during this review rest on animal or in vitro work, not human atorvastatin data, keeping them at yellow. The vitamin D claim's supporting human data runs the opposite causal direction from what would be needed here." What would fill it: "A human study directly measuring vitamin K2, selenium, or another candidate nutrient in an atorvastatin-treated subgroup (for example, high-dose or long-duration users) with a stated, bounded effect size, atorvastatin named as the studied drug rather than pooled into 'statins.'" Every one of those statements is still true of vitamin K2 and selenium. The tier was filled instead by a different parameter entirely, mitochondrial respiratory capacity, measured directly in an atorvastatin-named human arm.

Counter-evidence held on record

The LIFESTAT trial (Tier C for atorvastatin; simvastatin 40 mg/day only, PMID 28246888) found reduced complex II-linked respiration in simvastatin-treated patients regardless of myalgia status, but no significant reduction in muscle CoQ10 and comparable reactive oxygen species production between symptomatic and asymptomatic patients, suggesting this class of mitochondrial signal does not track muscle symptoms cleanly even for a different statin, and that different statins may hit different respiratory complexes. Mitochondrial content was preserved in both the atorvastatin trial above and in the isolated-cell work described under Oxidative stress and ATP production below, arguing against wholesale mitochondrial loss and for a more targeted enzyme-inhibition effect. This reflects the drug's own pharmacology, plausibly the same family of mechanisms underlying labeled statin-associated muscle symptoms, not a nutrient deficiency with an independent supplement fix. Do not present this as a reason to take a mitochondrial supplement beyond the CoQ10 finding already graded red above, and do not conflate the two mechanisms, shared-pathway CoQ10 depletion versus direct complex IV inhibition, when explaining either one to a reader.

Limits on what this shows

• Key negative / null findings: Valenti et al. found no discernible effect of atorvastatin alone on lipid peroxidation, no change in mitochondrial mass (citrate synthase activity unchanged), and no significant alteration of mitochondrial-function gene expression, arguing against a generalized oxidative injury and for a specific, concentration-gated redox effect. The polycystic ovary syndrome and pravastatin/atorvastatin comparison trials above could not be fully verified and are not treated as load-bearing quantitative evidence, only as directional, title-level record.
• At-risk subgroups: None defined by human atorvastatin data. The concentration-dependence in the cell and ex vivo work below means any at-risk subgroup would need markedly higher tissue drug exposure than standard oral dosing produces, which has not been shown to occur in any patient population.

Regulatory status

Oxidative stress, reactive oxygen species, and antioxidant enzymes are not named anywhere in the atorvastatin prescribing information.

Population evidence

Tier A, human, atorvastatin in cohort, protective direction: a case series of 83 patients with angiographically confirmed coronary stenosis on atorvastatin found thiobarbituric acid reactive substances (TBARS) significantly lower after more than 90 days of treatment than after fewer than 6 days (p=0.04), and ferric reducing antioxidant power (FRAP) significantly higher over the same comparison (832±101 vs. 688±75, p=0.01), alongside the expected LDL reduction ( ARYA Atherosclerosis, case series, treatment-duration groups of 27, 28, and 28 patients). A second human trial titled "Atorvastatin reduces malondialdehyde concentrations in patients with polycystic ovary syndrome" is indexed under that title; this review could not retrieve its full text or exact figures despite repeated attempts, so no quantitative result from it is reported here beyond the direction implied by the title itself. A third human trial, "The Influence of Pravastatin and Atorvastatin on Markers of Oxidative Stress in Hypercholesterolemic Humans" ( J Am Coll Cardiol 2008), is on record as testing atorvastatin directly against pravastatin and against each other's baseline, but this review could not retrieve its full text past a paywall, so no figures from it are cited here.

Mechanism

Present in both directions and concentration-dependent, not simply contested by weak evidence. At concentrations far above clinical exposure, atorvastatin directly inhibits mitochondrial complexes I and III, driving reverse electron transport and superoxide production (Valenti et al., human dermal fibroblasts and isolated mouse liver mitochondria, atorvastatin 3 to 100 µM; significant increase in DCF fluorescence and mitochondrial superoxide at 30 µM and above, p≤0.05 to p≤0.01). At the whole-organism level, atorvastatin's LDL-lowering effect itself reduces a major source of oxidized-lipid-driven oxidative stress, which is the more plausible route to the protective human trial findings above.

Concentration context

Added for this entry specifically because it is the deciding factor. Typical peak plasma atorvastatin concentration even at the maximum 80 mg dose is in the tens of nanomolar range. The pro-oxidant cell findings below required 1 to 160 µM, roughly 1,000- to 10,000-fold higher. The protective human trial findings above were obtained at standard clinical doses in treated patients. This is not a case of "no evidence either way"; it is a case where the harmful-direction evidence and the clinical-relevance evidence point at different concentration ranges entirely.

Counter-evidence held on record

Ex vivo human erythrocytes exposed to atorvastatin 1–10 µM for 48 hours showed significantly reduced superoxide dismutase, catalase, and glutathione peroxidase activity with dose-dependent membrane blebbing consistent with eryptosis (Rana et al., Turk J Biochem -family journal via SAGE, 2019, PMID search inconclusive, DOI 10.1177/1559325819869076), and a cardiomyocyte/skeletal-muscle-cell/endothelial-cell study found atorvastatin 40 µM tripled lipid peroxidation, roughly halved the GSH/GSSG ratio, and cut mitochondrial GPx4 expression by about 60 percent through Nrf2-xCT/GPx4 pathway suppression (Zhang et al., Front Cell Dev Biol 2022, PMC8927716). Both are real, atorvastatin-specific, reproducible findings and are not dismissed; they are held on record as concentration-bounded, cell-level evidence that does not, on the data available, reach the concentrations a treated patient's tissues experience. Do not state that atorvastatin causes oxidative stress in patients; the best available human clinical data run the other way. Equally, do not state that atorvastatin is a proven antioxidant therapy; the protective human findings are secondary endpoints in small trials, not the drug's approved indication. Do not convert either direction into a supplement recommendation; no dose of any antioxidant is recommended here.

Limits on what this shows

• Key negative / null findings: The ferritin meta-analysis below found no significant association between statin treatment duration and the size of the ferritin reduction (meta-regression p=0.26), arguing against a simple cumulative-dose depletion story even at the class level. The two atorvastatin cell studies above are not, on close reading, a true contradiction: one models direct high-concentration toxicity in otherwise healthy cells, the other models a lower, more clinically plausible concentration rescuing cells already under ischemic injury; but this dossier cannot resolve which, if either, better represents iron handling in an ordinary treated patient's tissue, since neither has a human correlate.
• At-risk subgroups: None defined by atorvastatin-specific data. The Korean cohort's hazard estimate applies to the pooled statin class, not to atorvastatin users identifiably.

Regulatory status

Iron, ferritin, and hepcidin are not named anywhere in the atorvastatin prescribing information.

Population evidence

No Tier A atorvastatin-specific source is confirmed. A study titled "Effect of atorvastatin on iron metabolism regulation in patients with chronic kidney disease – a randomized double blind crossover study" ( Renal Failure, PMID 30741616) is indexed in the literature as exactly the kind of atorvastatin-named, human, randomized iron-status trial this dossier's grading rules require for orange or red; this review could not retrieve its full text or specific figures despite repeated attempts, so it is recorded here as an unverified title-level lead, not as evidentiary support, and is flagged for a future review to reattempt. Tier C, class-level, atorvastatin not stratified: Kim et al. (working title reconstructed from indexed record), Possible link between statin and iron deficiency anemia: A South Korean nationwide population-based cohort study. Sci Adv. 2023;9. PMID 37889968. Propensity-matched retrospective cohort with self-controlled case series validation, Korean national health insurance data 2002–2015, 7,847 statin users (all statins pooled, including atorvastatin) versus 39,235 non-users. Adjusted hazard ratio for iron deficiency anemia during current statin exposure 4.84 (95% CI 3.40–6.89), rising further with cumulative exposure. Atorvastatin was one of seven statins pooled into this single exposure group and was not analyzed as a separate stratum.

Mechanism

Present in both directions, atorvastatin-specific, but only in cell models, and at different concentrations and in different injury contexts. Zhang Q, Qu H, Chen Y, et al. Atorvastatin Induces Mitochondria-Dependent Ferroptosis via the Modulation of Nrf2-xCT/GPx4 Axis. Front Cell Dev Biol. 2022;10:806081. PMC8927716. Human cardiomyocytes, mouse C2C12 skeletal muscle cells, and human umbilical vein endothelial cells exposed to atorvastatin 10–160 µM (40 µM primary dose): mitochondrial Fe²⁺ increased roughly threefold in cardiomyocytes and over fivefold in C2C12 cells (p<0.0001), driving iron-dependent ferroptotic cell death. In the opposite direction, at a roughly 40-fold lower concentration and in an injury-rescue rather than direct-toxicity context: atorvastatin 1 µM in H9C2 rat cardiomyocytes subjected to hypoxia/reoxygenation, and 10 mg/kg/day for two weeks in rats subjected to myocardial ischemia-reperfusion, reduced pathological intracellular iron accumulation, increased the iron exporter ferroportin, and improved cell viability and myocardial damage, dependent on SMAD7 activation suppressing hepcidin (Wiley, Cardiol Res Pract 2022;2022:3972829. PMC9666047; SMAD7 knockdown abolished the protective effect).

Serum ferritin, a related but distinct finding

Tier C, class-level: a systematic review and meta-analysis of nine observational studies (1,611 patients total; atorvastatin the most commonly represented statin but not analyzed as a separate stratum) found a weighted mean ferritin reduction of −39.5 ng/mL (95% CI −66.6 to −12.4, p=0.004) on statin therapy, attributed by the reviewing authors to statins' anti-inflammatory, pleiotropic effects rather than to iron loss, since ferritin is itself an acute-phase inflammatory marker as well as an iron-storage protein. A falling ferritin on a statin is not, by itself, evidence of falling iron stores, and this dossier does not treat it as one.

Counter-evidence held on record

Liu et al., Statins as a risk factor for anaemia: Evidence from genetic and epidemiological data. Br J Clin Pharmacol. 2025. This review located the citation but could not retrieve its full text past a paywall, so no odds ratio, confidence interval, or atorvastatin-specific finding from it is reported here; it is listed to document that a genetic (Mendelian randomization) approach to this exact question exists and should be reattempted in a future review, since that design is better suited than either cohort above to separating a causal statin effect from confounding by the cardiovascular disease being treated. Do not state that atorvastatin depletes iron; no human iron-status data exist for this drug specifically, and the strongest population signal available is pooled across seven different statins, not attributable to atorvastatin. Do not state that atorvastatin's cell-level iron effects mean it either causes or prevents ferroptosis in a treated patient's heart; both directions were shown in isolated cells at concentrations and in injury contexts that do not map cleanly onto ordinary oral dosing. No iron testing or supplementation is recommended by this dossier.

Limits on what this shows

• Why no grade: Yellow requires either mechanistic plausibility demonstrated at Tier B or class extrapolation at Tier C where at least one class member has real supporting biological data for the effect in question. Neither condition is met: no statin, atorvastatin or otherwise, has been shown in a biological system to alter copper status, and no atorvastatin copper-chemistry result exists outside synthetic coordination chemistry unrelated to human physiology. White requires a circulating claim to rebut; the consumer sources reviewed for this dossier's original claim audit and for this expansion make no copper claim for atorvastatin or for statins as a class. The category therefore sits outside all four tiers, and this dossier prints it rather than dropping it.
• What would fill it: A study directly measuring serum, erythrocyte, or urinary copper, or a validated functional copper marker such as ceruloplasmin oxidase activity, in an atorvastatin-treated human or animal cohort, with atorvastatin named as a study arm rather than pooled into "statins" or "lipid-lowering drugs." Failing that, an in vitro assay of atorvastatin's effect on a copper-dependent enzyme would establish or exclude a mechanism and would move this category to yellow or leave it firmly empty on stronger grounds.

What was searched

Searches conducted September 10, 2026 for atorvastatin together with copper, cuproptosis, ceruloplasmin, and trace element status returned no biological status study. The records that did surface were: (1) synthesis papers describing atorvastatin as a ligand in engineered transition-metal complexes with yttrium, niobium, molybdenum, and other metals, built for materials chemistry or novel-compound synthesis, not for any biological purpose; (2) a study of serum trace elements in dyslipidaemic subjects that this review could not access past a paywall, so neither its statin composition nor whether atorvastatin was included could be confirmed, and no figure from it is cited; (3) a rosuvastatin-plus-zinc-and-selenium supplementation trial in coronary artery disease patients, which excludes atorvastatin and concerns supplementation rather than atorvastatin's own effect on status.

The citation trap, noted explicitly

Multiple synthetic chemistry papers describe "atorvastatin-copper complexes" or "atorvastatin metal complexes," language that could be mistaken for a biological status finding. These are engineered compounds made by reacting atorvastatin with metal salts in a laboratory for spectroscopic, thermal, or antimicrobial-screening purposes, the same kind of citation trap this dossier's Lisinopril pilot documented for EDTA-lisinopril conjugates. They say nothing about copper handling in a person taking the drug and must not be cited as such.

Mechanistic plausibility, considered and not found

Unlike ACE, HMG-CoA reductase, the enzyme atorvastatin inhibits, is not a copper- or zinc-dependent metalloenzyme, so there is no target-level rationale analogous to even the weak zinc or copper extrapolations built for other drug classes in this dossier series. This absence of a plausible mechanism, combined with the absence of any status data, is why this category could not even reach yellow.

Counter-evidence held on record

There is none to hold, which is the finding. Nothing supports a copper burden or copper depletion claim for atorvastatin, and nothing rules one out. Absence of evidence is not evidence of safety. Do not publish "atorvastatin does not affect your copper levels," which the literature does not support, and do not publish a copper-testing or copper-supplement prompt attached to this drug, which the literature also does not support. If anything surfaces at all, it should say only that this has not been studied.

Limits on what this shows

• Population evidence, the null: Thomasen M, Misiakou MA, Li SS, et al. Metabolic, enterohepatic and gut microbial effects of atorvastatin in healthy men. Endocrine Connections. 2026;15(3):e250721. Randomized, placebo-controlled, double-blind crossover trial, 15 healthy men, atorvastatin 40 mg/day for one week escalated to 80 mg/day for a second week. Verbatim: "Microbiota composition was not affected by atorvastatin treatment." Bile acid composition did shift (taurine-conjugated primary bile acids increased, glycine-conjugated secondary bile acids decreased postprandially) and basal and postprandial glucagon rose versus placebo, with glucose and insulin unchanged, but the gut microbial composition endpoint itself was flatly null. This is the best-designed human evidence located, randomized, placebo-controlled, and atorvastatin-named rather than pooled into "statins."
• Key negative / null findings: The randomized crossover in healthy men above is the key null and the strongest-design human evidence in this entry; it directly contradicts a simple "atorvastatin disrupts the microbiome" reading. The two animal barrier/diversity studies also contradict each other in direction (harm to Akkermansia and barrier function in one HFD mouse model; partial normalization of diversity in a different HFD rat model), which this dossier reads as evidence that species, diet model, dose, and duration all matter more than any single "atorvastatin harms the gut" narrative would suggest.
• Confounding by indication: Applied explicitly, per this dossier's hard rules. The cross-sectional human comparison above compares people who differ by more than drug exposure: duration of hypercholesterolemia, diet, comorbidity, and lipid control likely differ systematically between treated and untreated groups, and between both patient groups and the healthy comparators. The randomized crossover in healthy men avoids this confound entirely by design, which is the main reason this entry does not grade higher than yellow despite the volume of animal and cross-sectional data.

Regulatory status

Microbiome, microbiota, and gut bacteria are not named anywhere in the atorvastatin prescribing information.

Population evidence, the mixed signal

A comparative, non-randomized study (design and exact atorvastatin dose not confirmed beyond the indexed abstract) of 15 untreated hypercholesterolemic patients, 27 atorvastatin-treated hypercholesterolemic patients, and 19 healthy subjects, 16S rDNA sequencing. Treated patients showed increased Faecalibacterium prausnitzii, Akkermansia muciniphila, and Oscillospira (taxa generally considered anti-inflammatory) and decreased Desulfovibrio and Bilophila wadsworthia (generally considered proinflammatory), while untreated patients showed increased Proteobacteria and the atherosclerosis-associated genus Collinsella. Set against this: "decreased bacterial diversity was observed in the atorvastatin-treated group" relative to the other two groups, a finding generally read as an adverse dysbiosis marker in the broader microbiome literature. This is a cross-sectional comparison of existing patient groups, not a before-and-after or randomized design, and cannot separate a drug effect from disease duration, diet, or lipid control differences between groups.

Mechanism

Present and genuinely bidirectional in animal models. In high-fat-diet mice, atorvastatin 10 mg/kg/day for 16 weeks suppressed Akkermansia muciniphila directly (confirmed by in vitro growth inhibition at 10 µM), reduced tight-junction proteins claudin-1 and occludin, and worsened LPS-driven NF-κB inflammatory signaling, an intestinal-barrier-harm finding (Frontiers in Microbiology 2021, 6 mice per group). In a separate high-fat-diet rat model, atorvastatin 5 to 20 mg/kg/day for 28 days partially normalized the HFD-disrupted Firmicutes/Bacteroidetes ratio and increased Chao1 and Shannon diversity indices toward healthy-control levels at the 15 mg/kg dose, while simultaneously reducing beneficial Lactobacillaceae and increasing Proteobacteria and Helicobacter ( Sci Rep 2018;8:1837, PMID 29330433, 42 Wistar rats). A third mouse study using antibiotic-depleted (not true germ-free) animals found atorvastatin's own cholesterol-lowering effect was significantly attenuated when gut microbiota was depleted, and that atorvastatin partly reversed a high-fat-diet-induced Firmicutes/Bacteroidetes shift in mice with intact microbiota ( J Clin Med 2020;9(5):1596, doi:10.3390/jcm9051596).

Direction check: microbiota acting on the drug

The antibiotic-depleted mouse study's finding that gut microbiota depletion blunts atorvastatin's own lipid-lowering effect is a case of the microbiome acting on the drug, not the drug acting on the microbiome, and is filed here as mechanistic context rather than as a burden finding, consistent with this dossier's direction-of-interaction rule.

Counter-evidence held on record

The randomized, placebo-controlled crossover in healthy men is itself the strongest piece of counter-evidence against any atorvastatin-microbiome burden claim: a null result, atorvastatin-named, at doses spanning the full standard-to-maximum range, in a design capable of detecting a real effect had one been present over the two-week exposure tested. Do not tell readers atorvastatin harms or helps their gut bacteria; the best human evidence found no effect at all, and the rest of the evidence is animal data pointing in different directions depending on model. Do not publish a probiotic or gut-health prompt attached to this drug; nothing in the evidence located supports one. Where a mixed human finding is mentioned, it must be presented with its cross-sectional, confounding-by-indication caveat attached, not as a clean before-and-after drug effect.

Limits on what this shows

• Key negative / null findings: Rana et al. explicitly report "no significant increase in hemolysis percentage" despite the clear eryptotic membrane markers, meaning membrane damage was demonstrated without demonstrated cell death or loss of oxygen-carrying red cells. No human trial measuring hemoglobin, hematocrit, VO2 max, or exercise oxygen kinetics specifically in atorvastatin-treated patients was located; a cross-sectional study of peak oxygen consumption across 4,941 adults exists in the literature but this review could not retrieve enough of its full text to determine whether atorvastatin was stratified separately from other statins, so it is not cited as evidence here.
• At-risk subgroups: None defined by any atorvastatin-specific human data.
• Dose and duration: The only dose-response data available is the ex vivo 1–10 µM range, roughly at or somewhat above typical peak plasma concentrations depending on dose, applied directly to isolated blood outside the body for 48 continuous hours, a very different exposure pattern from oral dosing with hepatic first-pass metabolism.

Regulatory status

Hemoglobin, hematocrit, anemia, and hemolysis do not appear in the atorvastatin label's adverse reactions or clinical laboratory findings sections, confirmed by full-text search for this review (see the pharmacokinetic basis table above). This is a genuine contrast with some other cardiovascular drugs whose labels do carry a hematologic laboratory finding.

Population evidence

None in humans at any tier. Tier B, ex vivo human blood: Rana RB, Jilani K, Shahid M, et al. Atorvastatin Induced Erythrocytes Membrane Blebbing. 2019 (SAGE journal, DOI 10.1177/1559325819869076). Erythrocytes from healthy donor blood banks exposed to atorvastatin 1–10 µM for 48 hours showed a significant, dose-dependent increase in mean cell volume (p<0.001 at the highest concentration) consistent with eryptotic membrane blebbing, mediated by reduced antioxidant enzyme activity and calcium influx (blebbing was prevented by the calcium channel blocker amlodipine). A single, unverified case report titled "Atorvastatin-induced anemia accompanied by elevated serum LDH levels" is indexed in the literature; this review could not retrieve its full text despite repeated attempts, so no clinical detail from it is reported here beyond its existence as a title-level record.

Mechanism

Present at the cell level only: oxidative-stress-mediated eryptosis, the same antioxidant-enzyme suppression described in the oxidative stress entry above, applied specifically to red cells. No mechanism for reduced erythropoiesis, marrow suppression, or hemoglobin synthesis interference is described anywhere in the atorvastatin literature located for this review, unlike the erythropoietin-mediated mechanism found for lisinopril in this same dossier series.

Counter-evidence held on record

The absence of a labeled hematologic finding after decades of atorvastatin's clinical use and the absence of measured hemolysis in the one ex vivo study located both weigh against a clinically meaningful oxygen-carriage effect at standard oral dosing. This is a different evidentiary picture from lisinopril, whose own label documents a small, frequent hemoglobin and hematocrit decrease; no equivalent regulatory signal exists for atorvastatin. Do not tell readers atorvastatin reduces their blood oxygen-carrying capacity or causes anemia; no human data support that, and the label carries no such finding. Do not present the ex vivo red-cell finding as evidence of clinical hemolysis, since the same study found no increase in hemolysis. New or unexplained anemia in a patient on atorvastatin should be worked up on its own merits, not attributed to the drug by default.

Limits on what this shows

• Key negative / null findings: The same study found mitochondrial mass unchanged (citrate synthase activity stable) and no significant alteration of mitochondrial-function gene expression, meaning the ATP deficit is a functional inhibition, not a loss of mitochondrial machinery. No human study has measured tissue ATP or phosphocreatine by 31 P magnetic resonance spectroscopy specifically in atorvastatin-treated patients; a study titled "Evaluation of skeletal muscle during calf exercise by 31-phosphorus magnetic resonance spectroscopy in patients on statin medications" exists in the literature, but this review could not retrieve enough of its full text to confirm whether atorvastatin specifically, rather than another statin, was in the studied cohort, so it is not cited as evidence here.
• At-risk subgroups: None defined by human data.
• Dose and duration: 30 to 100 µM in cell culture and isolated mitochondria is the only concentration range showing a significant ATP effect. Typical peak plasma atorvastatin concentration even at 80 mg/day is in the tens of nanomolar range, roughly 1,000-fold lower. No human dose or duration has been shown to reproduce this finding in tissue.

Regulatory status

ATP, energy metabolism, and high-energy phosphates are not named anywhere in the atorvastatin prescribing information.

Population evidence

None in humans. Tier B, atorvastatin in cohort: Valenti F, Pincigher L, Rizzardi N, et al. Atorvastatin Induces Bioenergetic Impairment and Oxidative Stress Through Reverse Electron Transport. Antioxidants 2025;14(10):1147. doi:10.3390/antiox14101147. Human dermal fibroblasts and isolated mouse liver mitochondria exposed to atorvastatin 3, 30, 50, and 100 µM. Basal and ATP-linked oxygen consumption showed significant reduction at 30 µM and above (p≤0.05), with lower ATP/ADP ratios described as "severe bioenergetic impairment." A companion finding: 10 nM coenzyme Q10 supplementation partially restored both CoQ10 levels and cellular energy status, mechanistically consistent with, but not a substitute for, the human CoQ10 depletion already graded red above.

Mechanism

Named: atorvastatin inhibits mitochondrial complexes I and III at these concentrations, driving reverse electron transport and reducing the proton-motive force available to ATP synthase. This is a distinct measurement from the mitochondrial respiratory capacity graded orange above; that entry counts oxygen-consumption capacity (respirometry), while this entry counts the ATP/ADP ratio itself, the closer proxy for cellular energy charge.

Counter-evidence held on record

The mitochondrial burden entry graded orange above found no change in creatine kinase and no significant group-level fall in VO2 max in atorvastatin-treated humans at a real, if high, clinical dose, both indirect markers that would be expected to move if ATP production were meaningfully impaired at standard dosing. No human functional-performance data located for atorvastatin specifically contradicts this directly, unlike lisinopril's own exercise-capacity trials; this is recorded as an absence of contradicting data rather than as confirming evidence. Do not tell readers atorvastatin lowers their cellular energy production at prescribed doses; the only evidence for that is cell and isolated-mitochondria work at concentrations far above what oral dosing produces in blood. Do not present the CoQ10 rescue finding in the cited cell study as a basis for a specific supplement dose; this dossier makes no dosing recommendation for any nutrient at this tier.